Organizational Design and Control across Multiple Markets: The Case of Franchising in the Convenience Store Industry

Dennis  Campbell; Srikant M. Datar; Tatiana  Sandino

Article | Accounting Review | November 2009

Organizational Design and Control across Multiple Markets: The Case of Franchising in the Convenience Store Industry

by Dennis Campbell, Srikant M. Datar and Tatiana Sandino

Abstract

Many companies operate units that are dispersed across different types of markets, and thus serve significantly diverging customer bases. Such market-type dispersion is likely to compromise the headquarter's ability to control its local managers' behavior and satisfy the divergent needs of different types of customers. In this paper we find evidence that market-type dispersion is an important determinant of delegation and the provision of incentives. Using a sample of convenience store chains, we show that market-type dispersion is related to the degree of franchising at the chain level as well as the probability of franchising a given store within a chain. Our results are robust to alternative definitions of market-type dispersion and to other determinants of franchising such as the stores' geographic distance from headquarters and geographic dispersion. Additional analyses also suggest that chains that do not franchise at all may cope with market-type dispersion by decentralizing operations from headquarters to their stores, and, to a weaker extent, by providing higher variable pay to their store managers.

Keywords: market dispersion; Decentralization; incentives; Business Headquarters; Geographic Location; Governance Controls; Distribution; Organizational Design; Franchise Ownership; Retail Industry;

Format: Print

Find at Harvard

Citation:

Campbell, Dennis, Srikant M. Datar, and Tatiana Sandino. "Organizational Design and Control across Multiple Markets: The Case of Franchising in the Convenience Store Industry." Accounting Review 84, no. 6 (November 2009): 1749–1779.

Prozac is widely hailed as “a breakthrough drug for depression.” In 2020, the World Health Organization (WHO) estimated that over 264 million people worldwide suffer from depression, and 800,000 die by suicide each year. In 2014, researchers calculated the economic impact of depression—in terms of lost productivity, absenteeism, and treatment costs—to be USD$63 billion per year in the United States alone. Depression’s toll on lives and livelihoods prompted the WHO to place Prozac on its list of essential medicines in 2009.

Tamoxifen is considered a “gold standard” treatment for millions of breast cancer patients. In 1985, twelve years after Imperial Chemical Industries (ICI), had first introduced tamoxifen in the United Kingdom (UK), the World Health Organization (WHO) designated it an essential cancer drug. In 2003, V. Craig Jordan, a leading tamoxifen researcher, estimated that “over 400,000 women are alive…as a result of tamoxifen therapy.”

Cephalosporins have played an under-appreciated role in treating deadly infections. Three generations of these antibiotics helped cut the rate of infections in patients recovering from operations in hospitals by more than half between the 1960s and 1990s. In 1986, just six years after “third-generation” cephalosporins were introduced, they accounted for 80% of the antibiotics administered in U.S. hospitals and have remained the top antibiotic given to hospitalized patients according to a 2010 survey. Some physicians call cephalosporins “wonder drugs” that, like penicillin, helped produce a “golden age” in antibiotic treatments; however, their story is not as well known.

Faculty & Research

Organizational Design and Control across Multiple Markets: The Case of Franchising in the Convenience Store Industry

Abstract

Citation:

About the Authors

More from these Authors